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Abstract
Introduction and purpose. Primary Ewing’s sarcoma arising from the bones of the head and neck region is extremely rare
representing only 1± 4% of all Ewing’s sarcoma cases. Previous reports suggest a better prognosis for that particular anatomic
site.The purpose of this study was to analyze the clinico-epidemiologic characteristics of that rare clinical presentation, as
well as its patterns of failure and prognosis following treatment.
Materials and methods. This study included a retrospective review of the medical records of patients with the diagnosis of
Ewing’s sarcoma of the head and neck region treated at King Faisal Specialist Hospital and Research Center between 1975
and 1996.
Results. Out of a total number of 24 cases analyzed, there were 17 males and 7 females with a ratio of 2.4:1. The median
age at diagnosis was 16.5 years. A painful swelling was the most common clinical presentation.The maxilla was the most
common site of presentation (9/24 cases). There were 3/24 cases who presented with metastatic disease at diagnosis.The
majority of patients (16/24 cases) had a tumor size >10 cm. Most patients were treated with systemic chemotherapy plus
localized irradiation following an initial biopsy.With a mean follow up of 3.4 years, the 5-year actuarial overall survival
(OS) for the whole group was 53%, while the 5-year actuarial disease-free survival (DFS) was 30%. These ® gures were
higher than those reported from our institution for young patients (£ 14 years treated for Ewing’s sarcoma in other
anatomic locations (30% v 15%). The response to chemotherapy was the only prognostic factor that affected both the
OS and DFS.
Conclusion. The prognosis of Ewing’s sarcoma of the head and neck region is slightly better than that of other anatomic
sites.The response to systemic chemotherapy is one of the most important prognostic factors affecting both DFS and OS of
Ewing’s sarcoma of the head and neck. Multimodality therapy consisting of an initial biopsy, aggressive combination
chemotherapy and localized radiotherapy is the treatment of choice for Ewing’s sarcoma of the head and neck region and
may result in long-term survival.
Introduction
Primary Ewing’s sarcoma arising in the head and
neck region is extremely rare, comprising 1± 4% of all
cases of Ewing’s sarcoma.
1,2 Most authors claim a
better prognosis for Ewing’s sarcoma of the head and
neck region as compared to that arising in other
anatomic locations.
1± 5The most commonly affected
bones in the head and neck region are the skull, the
mandible and the maxilla.
1There has also been case
reports of localized Ewing’s sarcoma affecting the
orbital roof,
3 the retropharynx
4 and the nasal cavity.
5
The aim of the present study was to review the cases
of Ewing’s sarcoma of the head and neck region
treated at our institution during the past 20 years,
aiming at a better understanding of the clinico-
epidemiologic characteristics of that rare anatomic
location. The details of treatment including surgery,
chemotherapy and radiation therapy, as well as the
patterns of failure are presented. Also, the various
potential prognostic factors affecting both the disease-
free (DFS) and the overall survival (OS) are
highlighted.
Materials and methods
The following study included a retrospective analysis
of data available from the medical records of 24 cases
of primary Ewing’s sarcoma arising in the head and
neck region, treated at the King Faisal Specialist
Hospital and Research Center during the period 1975
to 1996. The King Faisal Specialist Hospital and
Research Center is a tertiary care center serving the
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oncology referral center at present receiving patients
from all over the kingdom.
The analysis included reviewing various prognostic
factors that could affect the treatment outcome in
terms of DFS as well as OS.The charts were reviewed
for age, sex, presenting symptoms and signs and dura-
tion of symptoms. The primary tumor site was
determined for each patient. The tumor size as well
as the initial stage of presentation were determined
for all patients. Staging work-up of patients including
computerized tomography (CT) scan of the head
and neck, chest X-ray, CT scan of the chest, bone
scan, bone marrow biopsy and serum lactic dehydro-
genase (LDH) levels were reviewed.
The different treatment modalities adopted
including surgery, radiotherapy and chemotherapy
were reviewed in detail.The radiation therapy charts
were reviewed for the total dose given, the number
of fractions, the overall treatment time, the energy
used and the use of CT planing. Chemotherapy
details included timing of systemic chemotherapy,
agents used, number of cycles as well as the response
to chemotherapy treatment.
Patients were followed up regularly every 3 months
for the ® rst year, every 6 months in the subsequent 2
years and then yearly thereafter. Patients who were
lost to follow-up were censored from the survival
analysis at the time of last follow-up. None of those
patients participated in clinical trials.
The patterns of treatment failure, whether local
recurrence (LR) or distant metastasis (DM), were
studied in detail. Dates of local recurrence and distant
metastasis, as well as the initial site of DM were
determined. Both actuarial OS and DFS were
analyzed using the Kaplan± Meier method.
Results
Out of 24 evaluable patients, there were 17 males
and 7 females with a male to female ratio of 2.4:1.
The median age of the patients was 16.5 years (range
2± 33 years).A painful swelling was the most common
presentation found in more than 90% of patients as
shown in Table 1. The mean duration of symptoms
was 5.5 months (range 2± 12 months).
The maxilla was the most common site of presenta-
tion (9/24 cases). Metastasis at initial presentation
was found in only 3/24 cases. Most of our patients
had tumor size >10 cm in diameter (16/24 cases).
A bone marrow core biopsy from the iliac crest was
performed in 19 patients; and was found to be
in® ltrated by malignant cells in 1 patient only. The
LDH was assayed in 19 patients and was elevated in
12/19 (63%). A bone scan was done in 22/24 patients
(92%). It showed localized increased uptake opposite
the initial site of bony involvement in all 22 patients
with no evidence of metastatic spread.
The majority of patients had biopsy only (16/24
cases); while the remaining had either incomplete
excision (6/24 cases) or complete surgical excision
(2/24 cases).
The most common treatment modality was initial
biopsy followed by combined systemic chemotherapy
plus radiotherapy to the primary site involved. This
modality was adopted in 14/24 cases (58%). There
were various other treatment modalities, the most
common of which was surgical excision followed by
post-operative chemo-radiotherapy in 5/24 cases
(21%).
Systemic chemotherapy was delivered in 22/24
cases (92%). Two patients refused systemic chemo-
therapy treatment, 1 was treated with complete
surgical excision followed by post-operative radio-
therapy while the other was treated with incomplete
excision and refused post-operative irradiation. The
most common regimen given was VAC (vincristine,
adriamycin, cyclophosphamide; 10 patients) or VAC
alternating with IEP (ifosfamide, etoposide and
cisplatinum) given in 7 patients and VAIA (vincris-
tine, adriamycin, ifosfamide and actinomycin D) in 5
patients. The choice of chemotherapy regimen
depended on the protocol adopted during a given
period of time, i.e. patients treated from 1975 to
1980 received VAC alone, while those treated from
1980 to 1990 received VAC/IEP. All patients treated
from 1990 onwards received VAIA. There were only
13/22 patients (59%) who completed six or more
cycles of systemic chemotherapy. Complete remis-
sion was obtained in 57% of patients, while partial
remission occurred in 43% of patients. None of the
patients had disease progression on chemotherapy.
Radiotherapy was delivered in 20/24 cases (83%),
with a radical intent in 19/20 patients (95%). The
total radiation dose ranged from 3000 to 5600 cGy
with a median dose of 5040 cGy. There were 3/19
patients who received a total radiation dose £ 4000 cGy.
Table 1. Characteristics of evaluable patients
Patients’ characteristics Number of cases (%)
1. Sex
Male 17/24 (71%)
Female 7/24 (29%)
2. Symptoms
Swelling 23/24 (96%)
Pain and Tenderness 21/24 (87.5%)
Visual problems 8/24 (33%)
Anemia 8/24 (33%)
Fever 3/24 (12.5%)
3. Tumor size
5± 10 cm 8/24 (33%)
>10 cm 16/24 (67%)
4. Initial stage
Localized 21/24 (87.5%)
Metastatic 3/24 (12.5%)
5. Tumor site
Maxilla 9/24 (37.5%)
Mandible 6/24 (25%)
Orbit 4/24 (17%)
Skull 3/24 (12.5%)
Nasal Cavity 2/24 (8%)
12 A. Allam et al.The total dose of radiation given depended on the
treating physician. It did change to a more radical dose
(5400 cGy) over time. The majority of the patients
(13/20) were treated with 6 MV energy photons. Six
patients were treated with Cobalt 60 and the remaining
patient with 8 MV energy photons. CT planing was
used in 10/20 cases (50%).
There were 7/24 cases who developed LR (29%),
and 11/24 cases (46%) who developed DM.The lungs
were the most common single site of DM (27%);
there were 4/11 patients (36%) who had more than
one site of DM. Five out of 24 patients developed
both LR and DM.
With a mean follow-up time of 3.4 years, the 5-year
actuarial OS for the whole group of patients was
53%; while the actuarial 5-year DFS was 30%
(Fig. 1a and b). There was no statistically signi® cant
difference in 5-year OS and DFS between males and
females (54% vs 50% and 26% vs 36%, respectively).
Tumor size did not seem to have any impact on OS
and DFS.The actuarial 5-year DFS for patients with
tumor size of 5± 10 cm was 30% compared to 29%
for those with tumors >10 cm in diameter (p = 0.93).
Analysis of the survival results (both DFS and OS)
according to the primary tumor site did not show any
signi® cant impact of that factor on the treatment
outcome. The mandible had the highest 5-year OS
(80%), followed by the maxilla, skull and orbit (71%,
50% and 38%, respectively).This difference was not
statistically signi® cant.
The response to chemotherapy treatment was the
only prognostic factor which affected both the OS
and DFS. The 5-year OS for patients with complete
remission (CR) was 68% compared to 0% for patients
with partial remission (PR) to chemotherapy (p =
0.015); also the 5-year DFS for CR patients was
signi® cantly higher than that of PR patients (27% vs
0%; p = 0.02).
Discussion
Ewing’s sarcomas arising from the bones of the head
and neck region are extremely rare. Most cases in the
literature are reported sporadically as case reports.
The largest reported series until now is that of the
Intergroup Ewing’s Sarcoma Study (IESS) in 1987.
Siegal et al.
1 reported in that series on a total of 29
cases of Ewing’s sarcoma of the head and neck region
which represented 4% of all Ewing’s sarcoma cases
reported by the IESS group. In the present series,
Ewing’s sarcoma of head and neck constituted 9% of
all Ewing’s cases treated in this institute (24/259
cases).This relatively high ® gure might be attributed
to the fact that our hospital is the main referral
oncology center in the region. The male to female
ratio was 2.4:1, this is in accordance with the literature
being a disease where males are more frequently
affected.
6The median age at diagnosis for this study
was 16.5 years, which represents an expected ® gure
for Ewing’s sarcoma, a disease affecting primarily
patients <20 years of age.
7
The maxilla was the most common site of presenta-
tion in this study (9/24 cases).Although this represents
a rare site of primary presentation, yet there has been
a total of 22 cases of primary Ewing’s sarcoma of the
maxilla reported in the literature.
8,9
In the present series, most patients were treated
with initial biopsy followed by systemic
chemotherapy plus radical radiotherapy.This is due
to the fact that most of our patients have large
lesions (>10 cm) of the head and neck, where radical
surgery would be mutilating. Radical surgery can,
however, play an important role in achieving local
control in certain areas (e.g. mandible and skull),
especially in tumors <5 cm in diameter where the
treatment related morbidity would not be
increased.
5,10,11
The local control rate in the present study was
71%.This ® gure is lower than the 90% ® gure reported
in other series.
12 There are two main factors
affecting the local control rate, these are the initial
tumor size and the total radiation dose delivered.
The median dose in this study (5040 cGy) is
considered adequate to achieve local control by most
investigators.
12,13 Of the 3 patients who received a
total radiation dose £ 4000 cGy, only 1 developed
local recurrence.The lower local control rate ® gure
obtained in the present study seems to be attributed
to the large tumor size (>10 cm) in the majority of
our patients (16/24 cases). Most of our patients
present relatively late in the course of their disease
due to long distances, cultural reasons and lack of
efficient primary care hospitals in remote areas of
the kingdom.
The 5-year actuarial DFS as well as OS in the
present study (30% and 53%, respectively) are lower
than the ® gures reported by IESS (80% survival at 3
years). Again we attribute those lower ® gures mainly
to two factors: the larger tumor size at initial
presentation as well as the low compliance rate to
chemotherapy treatment, with only 59% of patients
completing more than six cycles.
Despite our lower survival rates, yet those are still
higher than the 15% 5-year relapse free survival
reported for a group of young patients (£ 14 years)
with the diagnosis of Ewing’s sarcoma in other
anatomic locations treated in our institute between
1980 and 1993 (personal communication). Similarly,
the IESS reported a higher median survival for head
and neck location in comparison to Ewing’s sarcoma
in other anatomic sites.
1
The only prognostic factor signi® cantly affecting
both DFS and OS in this study was the response to
chemotherapy. This ® nding is in agreement with the
recent articles that emphasize the importance of the
initial response to chemotherapy treatment as the
only signi® cant independent predictor of survival for
Ewing’s sarcoma patients.
14 It should be noted,
Ewing’s sarcoma of the head and neck 13however, that the power of subanalysis in this study
was low due to the small number of patients.
In the early phase of the present study, patients
were treated with the usual VAC combination
regimens, however, starting in 1995, with the
introduction of more aggressive chemotherapy, we
are now using VACA alternating with I/E (ifosfa-
mide, etoposide) for a total of 52 weeks. This new
alternating chemotherapy combination regimen has
already yielded a statistically signi® cant improvement
in DFS when compared to the standard VACA alone
in a phase III randomized study.
15 In conclusion,
Ewing’s sarcoma of the head and neck region carries
a slightly better prognosis than that in other sites.
Multimodality therapy consisting of an initial biopsy,
aggressive combination chemotherapy and localized
Fig. 1. (a) Overall survival for the whole group.
Fig. 1. (b) Disease-free survival for the whole group.
14 A. Allam et al.radiotherapy is the usual treatment of choice and
could result in long-term disease-free survival. Radical
surgery may be performed for local control in certain
anatomic locations (e.g. mandibular and skull lesions),
however, this needs to be followed by an adequate
reconstructive surgery.The response to chemotherapy
treatment remains one of the most important
prognostic factors affecting the DFS as well as the
OS of patients with Ewing’s sarcoma of the head and
neck region.
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